Acute 0 5 0 5 B-cancer
biphenotypic 6 18 6 18 I-cancer
leukemia 19 27 19 27 I-cancer

Acute 0 5 28 33 B-cancer
lymphoblastic 6 19 34 47 I-cancer
leukemia 20 28 48 56 I-cancer

Acute 0 5 57 62 B-cancer
myelogenous 6 17 63 74 I-cancer
leukemia 18 26 75 83 I-cancer

Adult 0 5 84 89 O
patients 6 14 90 98 O
must 15 19 99 103 O
have 20 24 104 108 O
an 25 27 109 111 O
Eastern 28 35 112 119 B-clinical_variable
Cooperative 36 47 120 131 I-clinical_variable
Oncology 48 56 132 140 I-clinical_variable
Group 57 62 141 146 I-clinical_variable
( 63 64 147 148 I-clinical_variable
ECOG 64 68 148 152 I-clinical_variable
) 68 69 152 153 I-clinical_variable
performance 70 81 154 165 I-clinical_variable
status 82 88 166 172 I-clinical_variable
of 89 91 173 175 O
0 92 93 176 177 B-lower_bound
or 94 96 178 180 O
1 97 98 181 182 B-upper_bound

Busulfan 0 8 183 191 B-clinical_variable
( 9 10 192 193 O
≥ 10 11 193 194 O
12.8 12 16 195 199 B-lower_bound
mg 17 19 200 202 I-lower_bound
/ 19 20 202 203 I-lower_bound
kg 20 22 203 205 I-lower_bound
IV 23 25 206 208 I-lower_bound
or 26 28 209 211 O
PO 29 31 212 214 O
) 31 32 214 215 O
and 33 36 216 219 O
cyclophosphamide 37 53 220 236 B-clinical_variable
( 54 55 237 238 O
≥ 55 56 238 239 O
120 57 60 240 243 B-lower_bound
mg 61 63 244 246 I-lower_bound
/ 63 64 246 247 I-lower_bound
kg 64 66 247 249 I-lower_bound
) 66 67 249 250 O

Busulfan 0 8 251 259 B-treatment
dose 9 13 260 264 O
may 14 17 265 268 O
be 18 20 269 271 O
adjusted 21 29 272 280 O
according 30 39 281 290 O
to 40 42 291 293 O
pharmacokinetics 43 59 294 310 O
targeting 60 69 311 320 O
a 70 71 321 322 O
daily 72 77 323 328 O
AUC 78 81 329 332 B-clinical_variable
of 82 84 333 335 O
5000 85 89 336 340 B-upper_bound
μmol 90 94 341 345 I-upper_bound
- 94 95 345 346 I-upper_bound
min 95 98 346 349 I-upper_bound
/ 98 99 349 350 I-upper_bound
L 99 100 350 351 I-upper_bound
, 100 101 351 352 O
per 102 105 353 356 O
institution 106 117 357 368 O
standard 118 126 369 377 O
of 127 129 378 380 O
practice 130 138 381 389 O

Chronic 0 7 390 397 B-cancer
lymphocytic 8 19 398 409 I-cancer
leukemia 20 28 410 418 I-cancer

Chronic 0 7 419 426 B-cancer
myelogenous 8 19 427 438 I-cancer
leukemia 20 28 439 447 I-cancer

Hodgkin 0 7 448 455 B-cancer
's 7 9 455 457 I-cancer
disease 10 17 458 465 I-cancer

Multiple 0 8 466 474 B-cancer
myeloma 9 16 475 482 I-cancer

Myelodysplasia 0 14 483 497 B-cancer

Myeloproliferative 0 18 498 516 B-cancer
disorder 19 27 517 525 I-cancer

Non 0 3 526 529 B-cancer
- 3 4 529 530 I-cancer
Hodgkin 4 11 530 537 I-cancer
's 11 13 537 539 I-cancer
lymphoma 14 22 540 548 I-cancer

Patient 0 7 549 556 O
's 7 9 556 558 O
donor 10 15 559 564 O
must 16 20 565 569 O
be 21 23 570 572 O
a 24 25 573 574 O
related 26 33 575 582 O
or 34 36 583 585 O
unrelated 37 46 586 595 O
human 47 52 596 601 B-clinical_variable
leukocyte 53 62 602 611 I-clinical_variable
antigen 63 70 612 619 I-clinical_variable
( 71 72 620 621 I-clinical_variable
HLA 72 75 621 624 I-clinical_variable
) 75 76 624 625 I-clinical_variable
8/8 77 80 626 629 O
allele 81 87 630 636 O
- 87 88 636 637 O
level 88 93 637 642 O
match 94 99 643 648 O
( 100 101 649 650 O
HLA 101 104 650 653 B-clinical_variable
- 104 105 653 654 I-clinical_variable
A 105 106 654 655 I-clinical_variable
, 106 107 655 656 O
B 108 109 657 658 B-clinical_variable
, 109 110 658 659 O
C 111 112 660 661 B-clinical_variable
and 113 116 662 665 O
DRB1 117 121 666 670 B-clinical_variable
) 121 122 670 671 O

Patients 0 8 672 680 O
must 9 13 681 685 O
be 14 16 686 688 O
undergoing 17 27 689 699 O
a 28 29 700 701 O
myeloablative 30 43 702 715 B-treatment
allogeneic 44 54 716 726 I-treatment
hematopoietic 55 68 727 740 I-treatment
cell 69 73 741 745 I-treatment
transplant 74 84 746 756 I-treatment
with 85 89 757 761 O
one 90 93 762 765 O
of 94 96 766 768 O
the 97 100 769 772 O
following 101 110 773 782 O
conditioning 111 123 783 795 O
regimens 124 132 796 804 O

Patients 0 8 805 813 O
must 9 13 814 818 O
have 14 18 819 823 O
a 19 20 824 825 O
life 21 25 826 830 B-clinical_variable
expectancy 26 36 831 841 I-clinical_variable
of 37 39 842 844 O
100 40 43 845 848 B-upper_bound
days 44 48 849 853 I-upper_bound

Patients 0 8 854 862 O
who 9 12 863 866 O
are 13 16 867 870 O
pregnant 17 25 871 879 B-pregnancy
or 26 28 880 882 O
lactating 29 38 883 892 O

Patients 0 8 893 901 O
who 9 12 902 905 O
are 13 16 906 909 O
seropositive 17 29 910 922 O
for 30 33 923 926 O
human 34 39 927 932 B-chronic_disease
immunodeficiency 40 56 933 949 I-chronic_disease
virus 57 62 950 955 I-chronic_disease
( 63 64 956 957 I-chronic_disease
HIV 64 67 957 960 I-chronic_disease
) 67 68 960 961 I-chronic_disease

Patients 0 8 962 970 O
who 9 12 971 974 O
have 13 17 975 979 O
undergone 18 27 980 989 O
any 28 31 990 993 O
prior 32 37 994 999 B-treatment
transplant 38 48 1000 1010 I-treatment

Patients 0 8 1011 1019 O
with 9 13 1020 1024 O
any 14 17 1025 1028 O
medical 18 25 1029 1036 O
illness 26 33 1037 1044 B-chronic_disease
or 34 36 1045 1047 O
concurrent 37 47 1048 1058 O
psychiatric 48 59 1059 1070 B-chronic_disease
illness 60 67 1071 1078 I-chronic_disease
which 68 73 1079 1084 O
, 73 74 1084 1085 O
in 75 77 1086 1088 O
the 78 81 1089 1092 O
investigators 82 95 1093 1106 O
' 95 96 1106 1107 O
opinion 97 104 1108 1115 O
, 104 105 1115 1116 O
can 106 109 1117 1120 O
not 109 112 1120 1123 O
be 113 115 1124 1126 O
adequately 116 126 1127 1137 O
controlled 127 137 1138 1148 O
with 138 142 1149 1153 O
appropriate 143 154 1154 1165 O
therapy 155 162 1166 1173 B-treatment

TBI 0 3 1174 1177 B-chronic_disease
( 4 5 1178 1179 O
≥ 5 6 1179 1180 O
1200 7 11 1181 1185 B-lower_bound
cGy 12 15 1186 1189 B-clinical_variable
) 15 16 1189 1190 O
and 17 20 1191 1194 O
cyclophosphamide 21 37 1195 1211 B-chronic_disease
( 38 39 1212 1213 O
120 39 42 1213 1216 O
mg 43 45 1217 1219 O
/ 45 46 1219 1220 O
kg 46 48 1220 1222 O
) 48 49 1222 1223 O

Total 0 5 1224 1229 B-clinical_variable
body 6 10 1230 1234 I-clinical_variable
irradiation 11 22 1235 1246 I-clinical_variable
( 23 24 1247 1248 I-clinical_variable
TBI 24 27 1248 1251 I-clinical_variable
) 27 28 1251 1252 I-clinical_variable
( 29 30 1253 1254 O
≥ 30 31 1254 1255 O
1200 32 36 1256 1260 B-lower_bound
cGy 37 40 1261 1264 I-lower_bound
) 40 41 1264 1265 O
and 42 45 1266 1269 O
etoposide 46 55 1270 1279 B-treatment
( 56 57 1280 1281 O
60 57 59 1281 1283 O
mg 60 62 1284 1286 O
/ 62 63 1286 1287 O
kg 63 65 1287 1289 O
) 65 66 1289 1290 O

pediatric 0 9 1291 1300 O
patients 10 18 1301 1309 O
must 19 23 1310 1314 O
have 24 28 1315 1319 O
Lansky 29 35 1320 1326 B-clinical_variable
score 36 41 1327 1332 I-clinical_variable
≥ 42 43 1333 1334 O
60 44 46 1335 1337 B-lower_bound
% 46 47 1337 1338 I-lower_bound

